Therefore, TGF-β2 may be a significant biomarker of poor prognosis in women with ovarian carcinoma, especially for advanced stage, poorly differentiated, and serous ovarian cancer patients. The gene discussed is TGFB2; the disease is ovarian serous adenocarcinoma.